BFBarbara Farrell

Barbara Farrell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barbara Farrell has a total of 215 co-authors. Here are the top co-authors by number of shared publications:

  • Lisa Dolovich

    Affiliation Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

    11 shared publications
  • Lisa M. McCarthy

    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada

    11 shared publications
  • Wade Thompson

    Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

    9 shared publications
  • Salima Shamji

    Assistant Professor in the Department of Family Medicine at the University of Ottawa

    8 shared publications
  • Anne Monahan

    Attending physician at the Bruyère Continuing Care Geriatric Day Hospital and Lecturer in the Department of Family Medicine at the University of Ottawa

    6 shared publications
  • Carlos Rojas-Fernandez

    Assistant Professor in the School of Pharmacy and the School of Public Health and Health Systems at the University of Waterloo and Schlegel Research Chair in Geriatric Pharmacotherapy at the Schlegel-University of Waterloo Research Institute on Ageing

    6 shared publications

Latest Publications

  • Development and Implementation of Deprescribing Guidelines

    by Aili V. Langford, Frank Moriarty, Darshna Goordeen, Barbara Farrell, Emily Reeve

  • Open Access

    A-I-D for cascades: an application of the Behaviour Change Wheel to design a theory-based intervention for addressing prescribing cascades in primary care

    by Lisa M. McCarthy, Barbara J. Farrell, Colleen Metge, Lianne Jeffs, Sameera Toenjes, M. Christine Rodriguez

    Background: Prescribing cascades, which occur when a medication is used to treat the side effect of another medication, are important contributors to polypharmacy. There is an absence of studies that evaluate interventions to address them. We describe an application of the Behaviour Change Wheel (BCW) to design theory-informed interventions for addressing prescribing cascades within interprofessional primary care teams. Methods: The BCW framework was applied to guide intervention development. This report describes the first seven steps. Three behaviours were developed based on data collected from two qualitative studies exploring why and how cascades occur across practice settings. A target behaviour was selected and the COM-B model was applied to identify relevant factors for interprofessional primary care teams. Relevant intervention types, policy options, and corresponding behaviour change techniques (BCTs) were identified, and intervention examples drafted. Prioritization of behaviours and intervention examples were guided by the APEASE criteria. Results: The three behaviours involved supporting: (1) healthcare providers (HCPs) to ask about, investigate and manage cascades, (2) the public to ask about prescribing cascades, and (3) the public to share medication histories and experiences with HCPs. The team selected the HCP behaviour, A-I-D (ask, investigate, deprescribe), for intervention development. Psychological capability and physical opportunity were the most relevant COM-B components. Ten intervention options comprised of BCTs were developed, which are ready for further prioritization by stakeholders. These can be grouped into: provision of educational materials for use by HCPs; provision of consultation or training to support HCPs; and knowledge mobilization strategies. Through the process, the team identified that development of a practice guidance tool, which assists HCPs to investigate and manage prescribing cascades, is needed to support further intervention development. Conclusions: The BCW framework guided the design of intervention examples to support primary HCPs practicing in interprofessional teams to address prescribing cascades. When identifying interventions for future consultation, creation of a practice guidance tool was prioritized as it underpins all proposed interventions for addressing prescribing cascades in practice. Further research is needed to determine what primary HCPs would need in this practice guidance tool and how it will be used in practice, to support its development.


  • Open Access

    What do clinical practice guidelines say about deprescribing? A scoping review

    by Aili Veronica Langford, Imaan Warriach, Aisling M McEvoy, Elisa Karaim, Shyleen Chand, Justin P Turner, Wade Thompson, Barbara J Farrell, Danielle Pollock, Frank Moriarty, et al.

    Introduction: Deprescribing (medication dose reduction or cessation) is an integral component of appropriate prescribing. The extent to which deprescribing recommendations are included in clinical practice guidelines is unclear. This scoping review aimed to identify guidelines that contain deprescribing recommendations, qualitatively explore the content and format of deprescribing recommendations and estimate the proportion of guidelines that contain deprescribing recommendations. Methods: Bibliographic databases and Google were searched for guidelines published in English from January 2012 to November 2022. Guideline registries were searched from January 2017 to February 2023. Two reviewers independently screened records from databases and Google for guidelines containing one or more deprescribing recommendations. A 10% sample of the guideline registries was screened to identify eligible guidelines and estimate the proportion of guidelines containing a deprescribing recommendation. Guideline and recommendation characteristics were extracted and language features of deprescribing recommendations including content, form, complexity and readability were examined using a conventional content analysis and the SHeLL Health Literacy Editor tool. Results: 80 guidelines containing 316 deprescribing recommendations were included. Deprescribing recommendations had substantial variability in their format and terminology. Most guidelines contained recommendations regarding forwho(75%, n=60), what(99%, n=89) andwhen or why(91%, n=73) to deprescribe, however, fewer guidelines (58%, n=46) contained detailed guidance onhowto deprescribe. Approximately 29% of guidelines identified from the registries sample (n=14/49) contained one or more deprescribing recommendations. Conclusions: Deprescribing recommendations are increasingly being incorporated into guidelines, however, many guidelines do not contain clear and actionable recommendations onhowto deprescribe which may limit effective implementation in clinical practice. A co-designed template or best practice guide, containing information on aspects of deprescribing recommendations that are essential or preferred by end-users should be developed and employed. Trial registration number: osf.io/fbex4.


  • Open Access

    Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects

    by Carina Lundby, Barbara Farrell, Amanda Wilson

    Anticholinergic‐induced cognitive impairment may be partially reversible upon cessation. A barrier to deprescribing of anticholinergics is the unknown risk of anticholinergic adverse drug withdrawal events (ADWE), with only limited information available on the incidence, timing and severity of anticholinergic ADWE. We report the case of a 76‐year‐old woman who experienced significant cognitive improvement following deprescribing long‐term use of a strong anticholinergic drug, doxepin, and dose reduction of another possible anticholinergic agent. The patient decided to abruptly stop taking doxepin, despite a planned careful taper with twice weekly monitoring, but did not experience any severe anticholinergic ADWE and subsequently had significantly improved cognitive function. Future research should focus on better understanding the risk of anticholinergic ADWE so that anticholinergic deprescribing decisions, including how often and by how much to taper, can be made confidently and safely.


  • Deprescribing

    by Lalitha Raman-Wilms, Barbara Farrell, Wade Thompson


  • Open Access

    Dix années de travaux liés aux guides de pratique clinique sur la déprescription

    by Barbara Farrell, Ida-Maisie Famiyeh, Matthew Preteroti, Vincent Vuong

  • Open Access

    Ten years of deprescribing guideline work

    by Barbara Farrell, Ida-Maisie Famiyeh, Matthew Preteroti, Vincent Vuong


  • Deprescribing

    by Lalitha Raman-Wilms, Barbara Farrell, Wade Thompson

  • Open Access

    A Proposed Curricular Framework for an Interprofessional Approach to Deprescribing

    by Barbara Farrell, Lalitha Raman-Wilms, Cheryl A. Sadowski, Laurie Mallery, Justin Turner, Camille Gagnon, Mollie Cole, Allan Grill, Jennifer E. Isenor, Dee Mangin, et al.

    Deprescribing involves reducing or stopping medications that are causing more harm than good or are no longer needed. It is an important approach to managing polypharmacy, yet healthcare professionals identify many barriers. We present a proposed pre-licensure competency framework that describes essential knowledge, teaching strategies, and assessment protocols to promote interprofessional deprescribing skills. The framework considers how to involve patients and care partners in deprescribing decisions. An action plan and example curriculum mapping exercise are included to help educators assess their curricula, and select and implement these concepts and strategies within their programs to ensure learners graduate with competencies to manage increasingly complex medication regimens as people age.